Drug Approval | March 27, 2024
FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
WINREVAIR is a breakthrough biologic for this rare, progressive disease
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Combination shows consistent benefit across prespecified post-progression outcomes
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
To accelerate the development of next-generation radioconjugates to treat cancer
Additional capacity broadens Grace’s fine chemical capabilities for API production
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Subscribe To Our Newsletter & Stay Updated
